# Shuttle Pharmaceuticals Holdings, Inc.: financial statements, quarterly

SHPH · Nasdaq · CIK 1757499 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/shph.md) · [Financials](/companies/shph/financials.md) · [Filings](/companies/shph/filings.md) · [Insiders](/companies/shph/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/shph/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [1,045](/filings/0001493152-24-045176.md) | [710 d](/filings/0001493152-25-008300.md) | [586](/filings/0001641172-25-009325.md) | [646](/filings/0001641172-25-023263.md) | [1,401](/filings/0001493152-25-022162.md) | [986 d](/filings/0001493152-26-014131.md) | [1,574](/filings/0001493152-26-023859.md) | [1,026](/filings/0001493152-26-044107.md) | [943](/filings/0001493152-25-022162.md) | [512 d](/filings/0001493152-26-014131.md) | [267](/filings/0001493152-26-023859.md) | [55.7](/filings/0001493152-26-044107.md) |
| Operating income | $k | [(1,599)](/filings/0001493152-24-045176.md) | [(1,283) d](/filings/0001493152-25-008300.md) | [(1,385)](/filings/0001641172-25-009325.md) | [(1,483)](/filings/0001641172-25-023263.md) | [(3,052)](/filings/0001493152-25-022162.md) | [(1,777) d](/filings/0001493152-26-014131.md) | [(2,951)](/filings/0001493152-26-023859.md) | [(3,910)](/filings/0001493152-26-044107.md) | [(2,267)](/filings/0001493152-25-022162.md) | [(2,788) d](/filings/0001493152-26-014131.md) | [(2,217)](/filings/0001493152-26-023859.md) | [(3,950)](/filings/0001493152-26-044107.md) |
| Interest expense | $k | [623](/filings/0001493152-24-045176.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,793)](/filings/0001493152-24-045176.md) | [(1,641) d](/filings/0001493152-25-008300.md) | [(1,731)](/filings/0001493152-25-022162.md) | [(2,031)](/filings/0001493152-25-022162.md) | [(3,784)](/filings/0001493152-25-022162.md) | [(1,598) d](/filings/0001493152-26-014131.md) | [(3,053)](/filings/0001493152-26-044107.md) | [(3,706)](/filings/0001493152-26-044107.md) | [(2,347)](/filings/0001493152-25-022162.md) | [(2,615) d](/filings/0001493152-26-014131.md) | [(2,152)](/filings/0001493152-26-044107.md) | [(3,146)](/filings/0001493152-26-044107.md) |
| Diluted EPS | $ per share | [(0.91)](/filings/0001493152-24-045176.md) | not reported | [(0.83)](/filings/0001641172-25-009325.md) | [(24.12)](/filings/0001641172-25-023263.md) | [(39.83)](/filings/0001493152-25-022162.md) | not reported | [(7.60)](/filings/0001493152-26-023859.md) | [(32.91)](/filings/0001493152-26-044107.md) | [(1.05)](/filings/0001493152-25-022162.md) | not reported | [(0.43)](/filings/0001493152-26-023859.md) | [(3.10)](/filings/0001493152-26-044107.md) |
| Basic EPS | $ per share | [(0.91)](/filings/0001493152-24-045176.md) | not reported | [(0.83)](/filings/0001641172-25-009325.md) | [(24.12)](/filings/0001641172-25-023263.md) | [(39.83)](/filings/0001493152-25-022162.md) | not reported | [(7.60)](/filings/0001493152-26-023859.md) | [(32.91)](/filings/0001493152-26-044107.md) | [(1.05)](/filings/0001493152-25-022162.md) | not reported | [(0.43)](/filings/0001493152-26-023859.md) | [(3.10)](/filings/0001493152-26-044107.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.9](/filings/0001493152-23-040531.md) | [2.6](/filings/0001493152-25-008300.md) | [1.4](/filings/0001493152-24-034901.md) | [0.7](/filings/0001493152-24-034902.md) | [0.2](/filings/0001493152-24-045176.md) | [1.9](/filings/0001493152-26-014131.md) | [4.5](/filings/0001641172-25-009325.md) | [4.8](/filings/0001641172-25-023263.md) | [2.1](/filings/0001493152-25-022162.md) | [0.3](/filings/0001493152-26-044107.md) | [1.1](/filings/0001493152-26-023859.md) | [0.1](/filings/0001493152-26-044107.md) |
| Current assets | $m | [7.0](/filings/0001493152-23-040531.md) | [5.6](/filings/0001493152-25-008300.md) | [4.4](/filings/0001493152-24-034901.md) | [2.5](/filings/0001493152-24-034902.md) | [0.4](/filings/0001493152-24-045176.md) | [2.2](/filings/0001493152-26-014131.md) | [5.0](/filings/0001641172-25-009325.md) | [5.2](/filings/0001641172-25-023263.md) | [3.3](/filings/0001493152-25-022162.md) | [0.5](/filings/0001493152-26-044107.md) | [2.5](/filings/0001493152-26-023859.md) | [0.4](/filings/0001493152-26-044107.md) |
| Total assets | $m | [7.4](/filings/0001493152-23-040531.md) | [6.0](/filings/0001493152-25-008300.md) | [4.8](/filings/0001493152-24-034901.md) | [2.8](/filings/0001493152-24-034902.md) | [0.7](/filings/0001493152-24-045176.md) | [2.5](/filings/0001493152-26-014131.md) | [5.3](/filings/0001641172-25-009325.md) | [5.5](/filings/0001641172-25-023263.md) | [3.5](/filings/0001493152-25-022162.md) | [10.5](/filings/0001493152-26-044107.md) | [11.8](/filings/0001493152-26-023859.md) | [22.8](/filings/0001493152-26-044107.md) |
| Current liabilities | $m | [0.8](/filings/0001493152-23-040531.md) | [1.0](/filings/0001493152-25-008300.md) | [1.5](/filings/0001493152-24-034901.md) | [1.4](/filings/0001493152-24-034902.md) | [1.7](/filings/0001493152-24-045176.md) | [1.5](/filings/0001493152-26-014131.md) | [1.8](/filings/0001641172-25-009325.md) | [1.7](/filings/0001641172-25-023263.md) | [2.0](/filings/0001493152-25-022162.md) | [8.0](/filings/0001493152-26-044107.md) | [8.3](/filings/0001493152-26-023859.md) | [3.5](/filings/0001493152-26-044107.md) |
| Total liabilities | $m | [1.8](/filings/0001493152-23-040531.md) | [1.9](/filings/0001493152-25-008300.md) | [2.0](/filings/0001493152-24-034901.md) | [2.0](/filings/0001493152-24-034902.md) | [2.0](/filings/0001493152-24-045176.md) | [1.8](/filings/0001493152-26-014131.md) | [2.0](/filings/0001641172-25-009325.md) | [1.9](/filings/0001641172-25-023263.md) | [2.1](/filings/0001493152-25-022162.md) | [8.2](/filings/0001493152-26-044107.md) | [8.5](/filings/0001493152-26-023859.md) | [3.6](/filings/0001493152-26-044107.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [5.6](/filings/0001493152-24-045176.md) | [4.1](/filings/0001493152-26-014131.md) | [2.8](/filings/0001493152-25-022162.md) | [0.8](/filings/0001493152-25-022162.md) | [(1.3)](/filings/0001493152-25-022162.md) | [0.7](/filings/0001493152-26-044107.md) | [3.3](/filings/0001493152-26-044107.md) | [3.6](/filings/0001493152-26-044107.md) | [1.4](/filings/0001493152-25-022162.md) | [2.3](/filings/0001493152-26-044107.md) | [3.3](/filings/0001493152-26-044107.md) | [19.2](/filings/0001493152-26-044107.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,535) d](/filings/0001493152-24-045176.md) | [(1,062) d](/filings/0001493152-25-008300.md) | [(1,239)](/filings/0001641172-25-009325.md) | [(1,399) d](/filings/0001641172-25-023263.md) | [(1,999) d](/filings/0001493152-25-022162.md) | [(2,690) d](/filings/0001493152-26-014131.md) | [(2,527)](/filings/0001493152-26-023859.md) | [(3,355) d](/filings/0001493152-26-044107.md) | [(2,627) d](/filings/0001493152-25-022162.md) | [(973) d](/filings/0001493152-26-014131.md) | [(2,417)](/filings/0001493152-26-023859.md) | [(568) d](/filings/0001493152-26-044107.md) |
| Capital expenditure | $k | not reported | [0.0 d](/filings/0001493152-25-008300.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-06-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [9,313](/filings/0001493152-23-028462.md) | [1,705](/filings/0001493152-24-034901.md) | [1,780](/filings/0001493152-24-034902.md) | [1,970](/filings/0001493152-24-045176.md) | [2,076](/filings/0001641172-25-009325.md) | [84.2](/filings/0001641172-25-023263.md) | [95.0](/filings/0001493152-25-022162.md) | [402](/filings/0001493152-26-023859.md) | [113](/filings/0001493152-26-044107.md) | [2,234](/filings/0001493152-25-022162.md) | [5,032](/filings/0001493152-26-023859.md) | [1,015](/filings/0001493152-26-044107.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,764,696 at 2026-09-21, from the cover of the [10-Q filed 2026-09-24](/filings/0001493152-26-044107.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.